We found a general increase of RB1CC1 in response to RSL3 and erastin in HepG2, gastric cancer MKN‐45, lung adenocarcinoma (LUAD) H1299, PC9 and A549, LUSC H226, pancreatic cancer (PACA) SW1990, HCC Bel‐7402 and colon adenocarcinoma HCT29 cells (Figures 1C and S1B). This evidence concerns the gene RB1CC1 and hepatocellular carcinoma.